Current Report Filing (8-k)
21 December 2022 - 11:06PM
Edgar (US Regulatory)
falseMA000134123500013412352022-12-212022-12-21
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2022
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
|
|
001-36332
|
|
20-1968197
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (781) 761-4904
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value per share
|
|
ALDX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 21, 2022, Aldeyra Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the submission of a New Drug
Application to the U.S. Food and Drug Administration for ADX-2191, an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated December 21, 2022
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Todd C. Brady
|
|
|
Name: Todd C. Brady M.D., Ph.D.
|
|
|
Title: Chief Executive Officer
|
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Nov 2023 to Dec 2023
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Dec 2022 to Dec 2023